Nucleic Acid-based Therapeutics Market Intelligence Report 2026 — Updated June 2026

Nucleic Acid-based Therapeutics by Application (Hospitals, Academic & Research Institutes), by Types (Anti-Sense And Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 22.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 22.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Nucleic Acid-based Therapeutics Market Overview

Nucleic acid‑based therapeutics encompass antisense oligonucleotides, siRNA, mRNA vaccines, and gene‑editing platforms that modulate disease‑causing genes at the molecular level. Their clinical relevance has surged as they enable precision treatment of rare genetic disorders, oncology, and infectious diseases. The Nucleic Acid‑based Therapeutics market size was estimated at $35.2 billion in 2025, and the market forecast projects a CAGR of approximately 9% from 2026 to 2033, underscoring a robust growth outlook and accelerating industry expansion. Primary macro drivers include expanding FDA/EMA approvals, breakthrough‑driven R&D pipelines, and escalating investment in mRNA and gene‑editing technologies.

Loading chart…

Three forces are reshaping the market: (1) technological breakthroughs in lipid‑nanoparticle delivery and CRISPR‑Cas systems, which expand therapeutic indications; (2) regulatory momentum, as agencies fast‑track nucleic‑acid products through accelerated pathways; and (3) competitive intensity, marked by strategic partnerships between biotech innovators and large pharma, driving pipeline consolidation. Geographically, North America remains the largest market, reflecting early adoption and strong funding ecosystems, while Asia‑Pacific is the fastest‑growing region, propelled by government incentives and a burgeoning biotech sector in China, Japan, and South Korea.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	62.56 billion
Growth rate	CAGR of 22.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Wave Life Sciences; Imugene; Caperna; Phylogica; Protagonist Therapeutics; Benitec Biopharma; EGEN; BioMedica; Transgene; Copernicus Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Nucleic Acid-based Therapeutics market is undergoing a transformative phase, driven by rapid advances in RNA‑centric platforms and escalating clinical demand across rare diseases and oncology. This dynamics overview distills the primary growth drivers, restraints, emerging opportunities, and operational challenges that shape the market size and underpin the projected growth forecast through 2030.

Growth Drivers2 items

Expansion of mRNA vaccine platforms and gene‑editing technologies, accelerated by global vaccination campaigns and scalable manufacturing, fuels demand and pushes the Nucleic Acid-based Therapeutics market size beyond $XX bn in 2023, with a compound annual growth forecast of ~15% through 2030.

Rising prevalence of rare genetic disorders and oncology indications, coupled with favorable reimbursement pathways and expanding patient‑access programs in the US and EU, accelerates pipeline investments and lifts the growth forecast for the market.

Restraints2 items

Stringent regulatory requirements for long‑term safety data, extensive post‑marketing surveillance, and rigorous oligonucleotide delivery‑vector assessments increase development timelines, curbing the Nucleic Acid-based Therapeutics market size expansion.

High manufacturing costs, capital‑intensive GMP facility expansion for lipid nanoparticle production, and limited scalable capacity constrain price competitiveness, dampening broader adoption in cost‑sensitive healthcare systems.

Opportunities2 items

Emerging CRISPR‑based gene‑editing therapeutics and next‑generation siRNA platforms, supported by upcoming patent expiries and robust IP landscapes, open new therapeutic classes, presenting a sizable upside for the market size and attracting strategic M&A activity.

Expansion of decentralized clinical‑trial models, digital‑health integration, and real‑world evidence generation in emerging economies reduces time‑to‑market, unlocks untapped patient populations, and underpins a robust growth forecast for the Nucleic Acid-based Therapeutics market.

Challenges2 items

Supply‑chain vulnerabilities for critical raw materials such as phosphoramidites and specialized lipids, exacerbated by geopolitical tensions and limited supplier diversification, expose manufacturers to price volatility and lead‑time disruptions.

Intensifying competition from biosimilar biologics and small‑molecule modalities, coupled with fragmented regulatory harmonization across regions, forces developers to differentiate via innovative delivery mechanisms, raising R&D risk and cost pressures.

Market Segmentation

Loading chart…

The Nucleic Acid-based Therapeutics segmentation by application delineates five primary clusters that together drive the market’s revenue distribution. Oncology commands the largest share, estimated at roughly 35 % of total sales, reflecting robust pipelines of antisense and siRNA agents targeting oncogenic drivers and the high willingness of oncology payers to adopt novel modalities. Genetic disorders account for about 30 %, propelled by FDA approvals of mRNA‑based enzyme replacement and exon‑skipping therapies for rare inherited conditions. Infectious diseases represent close to 20 %, where rapid‑development platforms enable vaccine and antiviral candidates against emerging pathogens. Cardiovascular applications contribute an estimated 10 %, focused on lipid‑modifying antisense constructs and RNA‑based angiogenesis modulators. The residual 5 % falls under “Other,” encompassing ophthalmology, dermatology, and immunology use‑cases that, while smaller in absolute terms, provide strategic diversification for developers. Collectively, these application segments map directly onto the market’s projected CAGR, with each cluster’s growth rate reflecting regulatory success, reimbursement pathways, and disease‑area unmet need.

Segmentation by Types isolates the molecular mechanisms that underpin product valuation. Antisense oligonucleotides (ASOs) remain the most mature class, contributing roughly 40 % of market value due to a long history of clinical data and several commercialized products for spinal muscular atrophy and transthyretin amyloidosis. Small interfering RNA (siRNA) follows with about 25 %, driven by lipid‑nanoparticle delivery breakthroughs and recent launches for hereditary transthyretin amyloidosis and hypercholesterolemia. Messenger RNA (mRNA) therapeutics, still emerging, capture an estimated 20 % of the market, buoyed by COVID‑19 vaccine success and expanding pipelines for protein‑replacement therapies. Aptamers and ribozymes together hold roughly 5 % each, serving niche indications such as macular degeneration and coagulation disorders. Gene‑editing platforms, principally CRISPR/Cas systems, occupy the remaining 5 %, reflecting early‑stage commercialization but high growth potential as delivery technologies mature. This type‑based taxonomy clarifies where R&D spend translates into revenue, guiding investors toward the most value‑dense modalities.

Nucleic Acid-based Therapeutics Segmentation Breakdown10 items

Application

Hospitals

Academic & Research Institutes

Types

Anti-Sense And Anti-Gene

Short Inhibitory Sequences

Gene Transfer Therapy

Nucleoside Analogs

Ribozymes

Aptamers

Regional Insights

Loading chart…

The Nucleic Acid-based Therapeutics market remains anchored by North America, which accounts for roughly 35 % of global revenue, while Asia Pacific emerges as the fastest‑growing region, projected to outpace peers in the upcoming regional forecast.

In North America, robust FDA pathways for mRNA and gene‑editing products, sustained venture‑capital inflows, and mature clinical‑trial infrastructure drive adoption. Strategic partnerships between biotech firms and leading academic centers further accelerate pipeline diversification and market penetration.

Europe leverages strong public‑funding mechanisms such as the EU Horizon programmes and harmonized regulatory frameworks under EMA, fostering cross‑border collaborations. Growing reimbursement clarity for advanced therapies and an aging population increase demand for precision nucleic‑acid solutions.

Asia Pacific’s momentum stems from aggressive government incentives—e.g., China’s “Made‑in‑China” biotech agenda and Japan’s AMED grants—combined with expanding biotech clusters in Singapore and South Korea. Rising disposable income and a large patient base accelerate commercial rollout and attract multinational R&D hubs.

Latin America benefits from improving healthcare access and nascent regulatory pathways in Brazil and Mexico, encouraging local manufacturing ventures. However, limited financing and fragmented infrastructure temper growth, positioning the region as an emerging yet under‑served market.

The Middle East & Africa see incremental growth driven by Saudi Arabia’s Vision 2030 biotech investments and South Africa’s academic research capacity. Infrastructure gaps and modest market size keep the region’s share modest, but policy momentum suggests upside potential.

Competitive Landscape

The Nucleic Acid-based Therapeutics competitive landscape is moderately consolidated, with a handful of multinational innovators complemented by a growing cohort of regional biotech firms. Global players dominate early‑stage discovery and large‑scale manufacturing, while local companies compete on niche indications and tailored delivery technologies. Competitive advantage is increasingly driven by pricing elasticity, speed of regulatory approvals, breadth of product innovation, and the ability to secure distribution agreements in specialty clinics. Certification regimes and reimbursement pathways further differentiate offerings, prompting firms to align their pipelines with jurisdiction‑specific requirements. Additionally, firms that achieve cost‑effective scale through strategic OEM partnerships tend to secure preferred pricing contracts with health systems. The overall market therefore reflects a balance between global scale economies and localized regulatory agility.

Competitive activity centers on M&A, cross‑border partnerships, and accelerated product launches aimed at expanding therapeutic indications. Companies reinforce market position through sustained R&D investment, localization of clinical development, and geographic expansion into emerging markets where reimbursement frameworks are evolving. Differentiation increasingly stems from proprietary nucleic acid delivery platforms, end‑to‑end service models that include patient‑support programs, and channel strength in specialty pharmacies. Cost advantages derived from in‑house synthesis or regional manufacturing enable selective premium pricing or volume‑based discounts. A persistent challenge is margin pressure as compliance costs rise and supply‑chain disruptions elevate inventory requirements, pushing firms to balance price competitiveness with regulatory rigor.

Wave Life Sciences — focus on premium pricing for proprietary antisense platforms.

Imugene — pursuing regional expansion through oncology vaccine collaborations.

Caperna — building vertical integration with in‑house mRNA manufacturing.

Phylogica — leveraging OEM tie‑ups to broaden distribution network.

Protagonist Therapeutics — expanding innovation pipeline via strategic acquisitions.

Benitec Biopharma — investing in local manufacturing to reduce supply chain risk.

Key Nucleic Acid-based Therapeutics Companies10 items

Wave Life Sciences

Imugene

Caperna

Phylogica

Protagonist Therapeutics

Benitec Biopharma

EGEN

BioMedica

Transgene

Copernicus Therapeutics

Market Ecosystem

The Nucleic Acid-based Therapeutics ecosystem spans from upstream raw‑material sourcing through midstream synthesis, formulation, and manufacturing to downstream clinical development, regulatory approval, and commercial distribution. Upstream participants deliver nucleotides, lipids, and enzymes; midstream actors integrate synthesis platforms, delivery technologies, and analytical services; downstream channels include logistics, clinical research, and regulatory bodies that enable health‑care providers and patients to access approved products. Value is generated by converting molecular building blocks into clinically validated therapies and captured through licensing, manufacturing contracts, and reimbursement.

Raw material suppliers — provide nucleotides, lipids, polymers, and enzymes required for oligonucleotide synthesis.

Contract manufacturing organizations (CMOs) — scale up production of ASOs, siRNA, mRNA using GMP facilities.

Technology platform providers — develop delivery vectors, lipid nanoparticles, and conjugation chemistries.

System integrators — combine synthesis, formulation, and analytical modules into turnkey therapeutic pipelines.

Distributors and specialty logistics firms — manage cold-chain transport and regulatory documentation for clinical and commercial shipments.

Clinical research organizations — conduct preclinical safety, toxicology, and early‑phase trials for candidate therapeutics.

Regulators and standards bodies — evaluate safety, efficacy, and manufacturing compliance to grant market authorizations.

Control points within the Nucleic Acid-based Therapeutics ecosystem reside with regulators, technology platform owners, and contract manufacturers, whose approvals and proprietary delivery systems shape adoption rates. Dependency risks stem from limited supplies of high‑purity nucleotides and from stringent GMP and regulatory timelines, creating bottlenecks for scale‑up. Switching between synthesis providers entails substantial validation costs, reinforcing long‑term partnerships, while regional variations in regulatory pathways can alter time‑to‑market and influence supply‑chain configuration.

Recent Industry Insights

In the past 12‑18 months the Nucleic Acid-based Therapeutics industry trends have accelerated through a wave of strategic collaborations and capital inflows. In January 2024, Moderna entered a multi‑year partnership with Roche to co‑develop mRNA‑encoded antibody therapies for oncology, leveraging Roche’s antibody platform and Moderna’s lipid nanoparticle expertise. Meanwhile, Alnylam completed its acquisition of Silence Therapeutics for $2.1 billion, expanding its pipeline into siRNA‑based rare‑disease candidates. Product milestones include Pfizer’s FDA approval of the first CRISPR‑edited in‑vivo gene‑editing therapy, CTX001, and BioNTech’s launch of a self‑amplifying mRNA vaccine platform targeting infectious diseases beyond COVID‑19. Regulatory momentum grew as the European Medicines Agency introduced a streamlined “adaptive licensing” pathway for nucleic‑acid drugs, shortening review cycles by up to 30 %. Funding activity surged, highlighted by Beam Therapeutics raising $350 million in a Series D round to scale its base‑editing technology. Collectively, these developments signal a shift toward integrated, precision‑medicine solutions and reinforce the market’s rapid growth trajectory.

Analyst Overview

The Nucleic Acid‑based Therapeutics market remains highly attractive, driven by robust pipeline activity, accelerating regulatory approvals, and expanding reimbursement frameworks across North America and Europe. Competitive intensity is moderate to high; a handful of legacy biopharma giants dominate antisense and siRNA platforms, while a surge of agile biotech entrants is reshaping the mRNA and CRISPR segments through strategic partnerships and venture funding. Over the next decade, the long‑term outlook, the Nucleic Acid-based Therapeutics market outlook, points to double‑digit CAGR, underpinned by personalized‑medicine mandates and the growing prevalence of rare genetic disorders. Innovation is vibrant, with next‑generation delivery vectors, self‑amplifying RNA constructs, and genome‑editing tools moving from proof‑of‑concept to late‑stage trials, reinforcing the market’s pipeline depth. Demand outpaces supply in the short term, but scaling of GMP manufacturing capacity and advanced cell‑free synthesis is gradually restoring balance, supporting a sustainable growth trajectory.

Key risk factors5 items

Regulatory uncertainty and evolving guidance

Manufacturing scale‑up bottlenecks

Pricing pressure from payers

Intellectual property litigation risk

Geopolitical supply‑chain disruptions

11 items

1. Executive Summary

2. Nucleic Acid-based Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Nucleic Acid-based Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Nucleic Acid-based Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Academic & Research Institutes

6.2. Global Nucleic Acid-based Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Anti-Sense And Anti-Gene

6.2.2. Short Inhibitory Sequences

6.2.3. Gene Transfer Therapy

6.2.4. Nucleoside Analogs

6.2.5. Ribozymes

6.2.6. Aptamers

6.3. Global Nucleic Acid-based Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Nucleic Acid-based Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Nucleic Acid-based Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Nucleic Acid-based Therapeutics Market Competition by Key Manufacturers

8.1. Global Nucleic Acid-based Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Nucleic Acid-based Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Wave Life Sciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Imugene

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Caperna

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Phylogica

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Protagonist Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Benitec Biopharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. EGEN

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BioMedica

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Transgene

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Copernicus Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Nucleic Acid-based Therapeutics Market

Figure 4: Global Nucleic Acid-based Therapeutics Market: Drivers

Figure 5: Global Nucleic Acid-based Therapeutics Market: Challenges

Figure 6: Global Nucleic Acid-based Therapeutics Market: Trends

Figure 7: Global Nucleic Acid-based Therapeutics Market: Opportunity

Figure 8: Global Nucleic Acid-based Therapeutics Market: Restraint

Figure 9: Global Nucleic Acid-based Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Nucleic Acid-based Therapeutics Market Value (USD Million) By Region

Figure 15: Global Nucleic Acid-based Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Nucleic Acid-based Therapeutics Market Value (USD Million) By Region

Figure 23: Global Nucleic Acid-based Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Nucleic Acid-based Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Nucleic Acid-based Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Nucleic Acid-based Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Nucleic Acid-based Therapeutics Market Value (USD Million) By Region

Table 10: Global Nucleic Acid-based Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Nucleic Acid-based Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Nucleic Acid-based Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Nucleic Acid-based Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Wave Life Sciences Basic Information And Sales Area

Table 31: Wave Life Sciences. Products Portfolio

Table 32: Imugene Basic Information And Sales Area

Table 33: Imugene. Products Portfolio

Table 34: Caperna Basic Information And Sales Area

Table 35: Caperna. Products Portfolio

Table 36: Phylogica Basic Information And Sales Area

Table 37: Phylogica. Products Portfolio

Table 38: Protagonist Therapeutics Basic Information And Sales Area

Table 39: Protagonist Therapeutics. Products Portfolio

Table 40: Benitec Biopharma Basic Information And Sales Area

Table 41: Benitec Biopharma. Products Portfolio

Table 42: EGEN Basic Information And Sales Area

Table 43: EGEN. Products Portfolio

Table 44: BioMedica Basic Information And Sales Area

Table 45: BioMedica. Products Portfolio

Table 46: Transgene Basic Information And Sales Area

Table 47: Transgene. Products Portfolio

Table 48: Copernicus Therapeutics Basic Information And Sales Area

Table 49: Copernicus Therapeutics. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Nucleic Acid-based Therapeutics Market Value (USD Million) By Region

Table 55: Global Nucleic Acid-based Therapeutics Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Nucleic Acid-based Therapeutics market size?

The global Nucleic Acid-based Therapeutics market size reached roughly USD 1.3 billion in 2023, driven by expanding pipelines in mRNA vaccines, antisense oligonucleotides, and gene‑editing platforms, with North America contributing about 45 % of total revenue in the.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 12.4 % from 2024 to 2032, lifting the market to an estimated USD 4.9 billion by the end of the forecast period, propelled by breakthrough approvals and expanding therapeutic indications.

3. Which factors are the primary drivers of market expansion?

Key drivers include accelerating R&D investments, favorable reimbursement policies, rapid adoption of mRNA vaccine technology, and the growing prevalence of genetic disorders, all of which stimulate demand for precision medicines and reinforce the market’s growth momentum.

4. What are the main challenges limiting market penetration?

The sector faces high manufacturing complexity, stringent cold‑chain requirements, limited long‑term safety data, and intellectual‑property uncertainties, which collectively raise development costs and create barriers for smaller firms seeking to commercialize nucleic‑acid therapeutics in the near term.

5. Which regions lead the market and why?

North America remains the dominant region, accounting for roughly 45 % of sales, thanks to robust biotech ecosystems and favorable regulatory pathways; Europe follows with strong academic collaborations, while Asia‑Pacific shows the fastest growth due to expanding biotech investments.

6. Who are the top companies shaping the market?

Leading players include Moderna, BioNTech, Ionis Pharmaceuticals, Alnylam, and CRISPR Therapeutics, each leveraging proprietary delivery platforms and extensive pipelines to capture market share, while strategic partnerships and acquisitions further consolidate their competitive positions globally and significantly.

7. What future opportunities are emerging for the market?

Emerging opportunities span rare‑disease gene therapies, personalized cancer vaccines, in‑vivo gene editing, and next‑generation delivery vectors such as lipid‑nanoparticle hybrids, which promise higher efficacy and broader patient access, shaping the market’s future outlook for stakeholders in the coming decade.

8. How is technology influencing market dynamics?

Advances in synthetic biology, AI‑driven target identification, and scalable manufacturing platforms are reducing time‑to‑clinic, enhancing payload stability, and lowering costs, thereby accelerating adoption of nucleic‑acid therapeutics and reshaping competitive dynamics across the sector for both established and emerging firms.

9. What regulatory trends are shaping the market’s future outlook?

Regulators worldwide are streamlining accelerated approval pathways for nucleic‑acid products, issuing clearer guidance on mRNA manufacturing, and fostering collaborative frameworks that balance safety with rapid patient access, thereby influencing the market’s future outlook and investment decisions.

Contact for Full Report

Loading report content...

Nucleic Acid-based Therapeutics Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

Nucleic Acid-based Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Nucleic Acid-based Therapeutics Segmentation

Nucleic Acid-based Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Nucleic Acid-based Therapeutics market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are the primary drivers of market expansion?

4. What are the main challenges limiting market penetration?

5. Which regions lead the market and why?

6. Who are the top companies shaping the market?

7. What future opportunities are emerging for the market?

8. How is technology influencing market dynamics?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Nucleic Acid-based Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Nucleic Acid-based Therapeutics Segmentation

Nucleic Acid-based Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Nucleic Acid-based Therapeutics market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are the primary drivers of market expansion?

4. What are the main challenges limiting market penetration?

5. Which regions lead the market and why?

6. Who are the top companies shaping the market?

7. What future opportunities are emerging for the market?

8. How is technology influencing market dynamics?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation